15 results about "Dose group" patented technology

The invention discloses an intensity modulated radiotherapy plan quality assurance method and system based on virtual prediction, and the method comprises the steps: extracting complexity parameters from a radiotherapy plan RTplan of a patient, extracting three-dimensional dose distribution characteristics from RTdense, calculating the preprocessing data of a flux diagram through combining with TPS, and designing and training an end-to-end convolutional neural network model. The model comprehensively analyzes plan complexity, dosiomics features, and flux image features to predict virtual measurement flux and Gamma pass rate. Through multi-dimensional data fusion, the prediction accuracy and the QA efficiency are remarkably improved, the quality of the radiotherapy plan can be automatically evaluated in advance, the radiotherapy process is assisted to be accelerated, and the treatment precision is improved.

The invention belongs to the technical field of medical data processing, and discloses a multi-drug combined dose dynamic optimization method, equipment and a medium. The method comprises the following steps: constructing a multi-drug time-varying structure causal diagram; based on historical clinical observation data, performing causal effect learning on the structural causal diagram; in response to the current state input of a patient to be treated, carrying out anti-factual reasoning on the structure causality graph; an optimal dose combination is calculated that maximizes the desired efficacy and minimizes the uncertainty. According to the method, the structural causal diagram is constructed, the physiological state of the patient, multi-drug dose intervention, the pharmacokinetic process and the clinical outcome are uniformly modeled in the same causal framework, and the causal influence of the drug dose on the clinical outcome and the non-causal association relationship can be distinguished under the condition that historical clinical observation data are mixed and biased; and on this basis, anti-factual reasoning is performed on different dose combinations, so that potential clinical outcome distribution under assumed intervention conditions is obtained.

The invention discloses an application of pegylated irinotecan in preparation of a medicine for preventing and / or treating triple-negative breast cancer brain metastasis diseases, which is shown by in-vivo imaging observation and lifetime observation of high, medium and low dose groups of pegylated irinotecan with a specific structure. The high-dose group, the medium-dose group and the low-dose group all have a definite anti-tumor effect, bioluminescence signal values are inhibited to different degrees, the lifetime is prolonged, and the lifetime of the high-dose group and the lifetime of the medium-dose group are remarkably longer than that of the NKTR-102 group.

The invention relates to a traditional Chinese medicine preparation, in particular to application of a compound live brain soothing capsule in preparation of a medicament for treating insomnia. The dosage of the medicine is 200 mg / kg. Experiments show that the sleep improvement effect of the compound Shuonaoshu capsule on an anesthesia reviving experiment evaluation test medicine, a high-dose group (200 mg / kg) of the compound Shuonaoshu capsule can effectively prolong sleep time, dose dependence exists, sleep quality can be moderately improved, the higher the concentration is, the more obvious the improvement effect is, and the more obvious the effect is. The invention reveals that the compound Liangjinshu capsule has a treatment effect on insomnia, and is expected to provide a certain experimental basis for the development of new drugs for insomnia.

The present disclosure relates to a dose detection system for use in combination with a medication delivery device in which a dose setting member rotates relative to an actuator during dose delivery. The dose detection system includes a module which is removably attached to the medication delivery device. The module includes a dosing component attached to the actuator during dose delivery. The dosing component includes a light source and a light sensor. A sensed element is attached to the dose setting member and includes surface features detectable by the light sensor.

This disclosure relates to a method for determining bioeffective dose, wherein the method includes: detecting the boron concentration C of each voxel in the target at multiple time points. B ; Calculate C B The corresponding biological effect value (RBE) B Determine C B and RBE B The first association relationship, based on the first association relationship, determines the connection through C. B Characterized RBE B ; Calculate C B The corresponding first physical absorbed dose rate D B And other physical absorbed dose rates corresponding to dose components other than boron, and physical dose rate distribution D phy According to RBE B and D B The product of the other dose components and the product of other biological effect values ​​and other physically absorbed dose rates is used to calculate C. B The combined biological effect value (CBE); based on CBE and D phy Calculate the biologically effective dose D bio According to this disclosure, it is beneficial to determine the appropriate irradiation time for different voxels during BNCT in order to obtain better therapeutic effects.

The invention discloses an artificial intelligence-driven personalized drug dosage dynamic adjustment method and system. The method comprises the following steps: acquiring multi-source heterogeneous data of a patient, preprocessing and constructing to obtain graph structure data; performing feature extraction on the graph structure data by using a trained graph convolutional network to obtain high-order features of the patient, and predicting treatment conditions of the patient under different dose combinations; based on the high-order features, searching an optimal dose combination in a medication dose solution space by using an improved genetic algorithm, and generating a medication dose adjustment scheme; generating a risk assessment report based on the drug dosage adjustment scheme in combination with the multi-source heterogeneous data, and prompting the potential risk of dosage adjustment; and continuously collecting subsequent treatment feedback data of the patient and using the subsequent treatment feedback data to optimize the parameters of the graph convolutional network and the weight of the fitness function in the improved genetic algorithm. According to the method, the precision and dynamic adjustment of the medication dosage are realized.

The invention discloses application of hyperoside to treatment of endometriosis, and aims to evaluate whether hyperoside has an anti-fibrosis effect when applied to a rat endometriosis model by taking fibrosis as a treatment target. The method comprises the following steps: constructing a rat endometriosis model through an autotransplantation method, dividing molded rats into a low-dose group, a medium-dose group, a high-dose group, a model group and a western medicine control group 4 weeks after successful modeling, and laparotomizing and taking out ectopic lesions after respectively taking medicines for 4 weeks. HE staining and masson staining methods are used for mutually proving the fibrosis degree, the expression conditions of fibrosis indexes a-SMA, Co-1, CTGF and Fn are detected in an immunohistochemical mode, and the anti-fibrosis effect of hyperoside is evaluated. As a result, hyperoside can prevent the development of fibrosis in endometriosis, and thus hyperoside can be used as a drug for treating or preventing fibrosis in endometriosis.

The present invention belongs to the field of biomedical technology and relates to the application of geniposidic acid in the preparation of drugs for preventing or treating depression. The geniposidic acid described in the present invention can be applied in the preparation of drugs for preventing or treating depression, and the therapeutic effect of geniposidic acid can be comparable to that of the commonly used existing antidepressant drug fluoxetine. Geniposidic acid can effectively reduce the immobility time in the tail suspension test; it can effectively reduce the immobility time in the forced swimming test; in the sucrose preference test, the high-dose geniposidic acid is equivalent to the positive control drug fluoxetine, indicating that geniposidic acid (5 mg / kg) alleviates the anhedonic behavior of CUMS mice; there are significant changes in the open field behavior indexes of the fluoxetine group and each dose group of geniposidic acid, among which the effect of the geniposidic acid (5 mg / kg) group is the same as that of fluoxetine (10 mg / kg). Geniposidic acid (5 mg / kg) can effectively reduce the levels of inflammatory factors IL-1β, TNF-α, and IL-6 in the mouse brain tissue. It can be known from the research data analysis that the therapeutic effect of geniposidic acid in treating depression can be comparable to that of the commonly used existing antidepressant drug fluoxetine.

The invention discloses a method for establishing a rat radiodermatitis model. The method comprises the following steps: S1, setting a control group, a low-dose group, a medium-dose group, a high-dose group and a false irradiation group; the control group is not irradiated, and the skin state of the rats under the condition that the rats are not damaged by radiation is observed; the total irradiation dose of the low-dose group is 35Gy; the total irradiation dose of the medium dose group is 40Gy; the total irradiation dose of the high-dose group is 45Gy; s2, selecting rats, shaving and cleaning radiation parts of the rats, and performing anesthesia treatment on the rats; s3, a 6MeV electron accelerator is adopted for radiation irradiation, the irradiation time of a low-dose group is 5.83 minutes, the irradiation time of a medium-dose group is 6.67 minutes, and the irradiation time of a high-dose group is 7.5 minutes; s4, after irradiation is completed, the rats are removed and transferred into a clean cage, the reaction of the rats after irradiation is observed, and the initial conditions of skin injuries including erythema and swelling are recorded; experiments should regularly record the health condition of the rat.

The invention provides an application of xanthoceras sorbifolia 4-flavor decoction in anti-inflammation and detumescence of RA rats. According to the present invention, the determination is performed according to the comparison of the toe and ankle swelling degree and the AI score of each group of rats at different time, the pathological change of the ankle joint of the rats, and the experimental results of the inhibition conditions of the RF, the ASO, the CRP, the TNF-a, the IL-6 and the MMP-9 factors in the serum of the rats; the xanthoceras sorbifolia-4-flavor decoction can significantly inhibit the increase of RF, CRP, TNF-a and IL-6 in serum. Wherein the ankle joints of the rats in the normal group do not have definite inflammatory cell infiltration and vascular nebula generation; model group rats find out synovial growth, nebula generation and large-scale inflammatory cell infiltration, and CIA rat ankle joint in-vivo observation finds out; the positive group still has synovial hyperplasia and inflammatory cells; in low dose and medium dose administration, only slight synovial hyperplasia, formation of a small amount of small blood vessels and generation of inflammatory cells exist, and in a high dose group, the pathological structure that the synovial hyperplasia is reduced and the inflammatory cells are reduced is improved to a certain extent.

The invention provides a method for researching a Wnt signal channel regulation mechanism of a myocardial infarction rat by using radix astragali and radix salviae miltiorrhizae qi-tonifying dropping pill and application, and belongs to the technical field of traditional Chinese medicines. The research method comprises the following steps: step 1, randomly dividing prepared myocardial infarction rat models into a radix astragali-ginseng qi-tonifying dropping pill high-dose group, a radix astragali-ginseng qi-tonifying dropping pill medium-dose group, a radix astragali-ginseng qi-tonifying dropping pill low-dose group, a western medicine group and a model group, and respectively performing four batches of experiments in the first, fourth, seventh and fourteenth days; 2, index detection is carried out on the second day after the corresponding intervention time ends; and step 3, statistical analysis. Attention is given to a Wnt signal channel, regulation and control of the channel have important significance on secondary prevention of myocardial infarction, but at present, drug intervention researches aiming at the mechanism are not more, and the research takes Chinese patent medicines as test drugs, positive control is set, the treatment value of traditional Chinese medicines on myocardial infarction is explored, the advantages of the traditional Chinese medicines are explored, and a basis is provided for optimizing a clinical treatment scheme.

The invention relates to the technical field of pharmacology, in particular to application of ursodesoxychoberberine to preparation of a medicine for preventing and / or relieving and / or treating pulmonary fibrosis. The preparation for preventing and / or relieving and / or treating pulmonary fibrosis is characterized in that the preparation contains ursodesoxychoberberine. The preparation also comprises one or more of a pharmaceutically acceptable carrier, an auxiliary material and an excipient. Dosage forms of the preparation include but are not limited to capsules, particles, tablets, pills, spray, suppositories, aerosols, powder aerosols, patches, oral liquid or injection. The indexes of a low-dose group and a high-dose group of the ursodesoxychoberberine are remarkably improved, the effect of the high-dose group is the best, and particularly, the high-dose group of the ursodesoxychoberberine is remarkably superior to that of a pirfenidone (PFD) positive drug group in the aspect of improving the body weight of a mouse. The results show that the ursodesoxychoberberine has a good development prospect as a candidate drug for resisting pulmonary fibrosis.

The present application relates to the technical field of pathological evaluation, and particularly relates to a heat stroke myocardial injury mouse model construction and evaluation method, comprising constructing a heat stroke myocardial injury mouse model by increasing the core body temperature, determining the key time point of the intervention effect of different dose gradients of GDF15 after the heat stroke modeling; obtaining the cTn-I index and the ALT index based on the key time point, determining the injury type ratio based on the normalized values of the cTn-I index and the ALT index to determine the injury type of the heat stroke; adjusting the evaluation strategy in response to the injury type, obtaining the recovery rate of the cTn-I index and the ALT index of the model control group at each time point to determine the myocardial injury degree and the liver injury degree at the corresponding time point; obtaining the average recovery rate of the ALT of each dose group to determine the ALT recovery rate ratio between different dose groups, and adjusting the observation length of the dose group. The present application can distinguish the injury types by constructing the heat stroke myocardial injury model, and cannot adapt to the dynamic changes of different injury types.

The invention belongs to the technical field of application of compound radix astragali oral liquid for strengthening the spleen, and particularly relates to application of the compound radix astragali oral liquid for strengthening the spleen in repairing digestive tract mucosal lesions of functional dyspepsia animals. Mucosal lesion, dysfunction and low-grade inflammation states are simulated. And randomly dividing the successfully molded rats into a model control group, a positive drug group and low, medium and high dose groups of the compound astragalus membranaceus spleen-tonifying oral liquid, and continuously performing intragastric administration for 21 days. Detection shows that the oral liquid can remarkably reduce the serum D-lactic acid level and the serum proinflammatory factor content, improve the pathological damage of stomach and duodenum tissues and improve the animal holding power. The invention provides a systematic method for evaluating that the oral liquid repairs the juvenile FD mucosal lesion, verifies the effects of enhancing the barrier and relieving inflammation, and also provides an effective tool for research and development of similar drugs.